Zhitong Finance App News, East Asia Pharmaceutical (605177.SH) issued an announcement. Recently, Jiangxi Shanyuan Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received the European Pharmacopeia Certificate of Applicability for Flubiprofen APIs (“CEP Certificate”) issued by the European Medicines and Healthcare Quality Administration (EDQM). Flubiprofen is a non-steroidal anti-inflammatory drug. Clinically, it is mainly suitable for rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, etc., and can also be used for symptomatic treatment of soft tissue diseases (such as sprains and strain injuries) and mild to moderate pain (such as menstrual pain, post-operative pain, toothache, etc.).

Zhitongcaijing · 1d ago
Zhitong Finance App News, East Asia Pharmaceutical (605177.SH) issued an announcement. Recently, Jiangxi Shanyuan Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received the European Pharmacopeia Certificate of Applicability for Flubiprofen APIs (“CEP Certificate”) issued by the European Medicines and Healthcare Quality Administration (EDQM). Flubiprofen is a non-steroidal anti-inflammatory drug. Clinically, it is mainly suitable for rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, etc., and can also be used for symptomatic treatment of soft tissue diseases (such as sprains and strain injuries) and mild to moderate pain (such as menstrual pain, post-operative pain, toothache, etc.).